Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-02-20
2004-05-11
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S183000
Reexamination Certificate
active
06734199
ABSTRACT:
TECHNICAL FIELD
The present invention relates to substituted benzylthiazolidine-2,4-dione derivatives effective for the prevention and/or therapy of metabolic diseases such as diabetes and hyperlipidemia as agonists of peroxisome proliferator-activated receptor (abbreviated as PPAR) being nuclear receptor, in particular, as agonists of human PPAR, their addition salts, process for preparing them, and medicinal compositions containing these compounds.
BACKGROUND TECHNOLOGIES
The peroxisome proliferator-activated receptor(PPAR) is a ligand-dependent transcription factor that belongs to nuclear receptor superfamily similarly to steroid receptor, retinoid receptor, thyroid receptor, etc., and three isoforms (&agr; type, &bgr; (or &dgr;) type and &ggr; type) with different histological distribution have been identified hitherto in human and various animal species (Proc. Natl. Acad. Sci., 1992, 89, 4653). Thereamong, the PPAR&agr; is distributed in the liver, kidney, etc. with high catabolic capacity for fatty acids and, particularly high expression is recognized in the liver, (Endo-crinology, 1995, 137, 354), positively or negatively controlling the expression of genes related to the metabolism and the intracellular transport of fatty acids (e.g. acyl CoA synthetic enzyme, fatty acid-binding protein and lipoprotein lipase) and apolipoprotein (AI, AII, CIII) genes related to the metabolisms of cholesterol and triglycerides. The PPAR&bgr; is expressed ubiquitously in the tissues of organisms including around nerve cells. At present, the physiological significance of PPAR&bgr; is unclear. The PPAR&ggr; is highly expressed in the adipocytes and contributed to the differentiation of adipocytes (J. Lipid Res., 1996, 37, 907). In this way, each isoform of PPAR play specific functions in the particular organs and tissues.
Moreover, it is reported that a knock-out mouse of PPAR&agr; exhibits hypertriglyceridemia with ageing and becomes obesity mainly by increasing the white adipocytes (J. Biol. Chem., 1998, 273, 29577), hence the relevance between activation of PPAR&agr; and decreasing action of lipids (cholesterol and triglyceride) in blood is suggested strongly.
On the other hand, fibrates and statins are widely used so far as the therapeutic drugs for hyperlipidemia. However, the fibrate type drugs have only weak decreasing action of cholesterol, while the statin type drugs have weak decreasing action of free fatty acids and triglycerides. Moreover, with respect to the fibrate type drugs, various adverse effects such as gastrointestinal injury, anthema, headache, hepatic disorder, renal disorder and biliary calculus are reported. The reason is considered to be due to that the fibrate type drugs exhibit extensive pharmacological function.
On the other hand, it is ascertained that the major intracellular target protein of Troglitazone, Pioglitazone and Rosiglytazone being a series of thiazolidine-2,4-dione derivatives that are therapeutic drugs for type II diabetes (noninsulindependent diabetes) and exhibit blood glucose-decreasing action, improving action on hyperinsulinemia, etc. are PPAR&ggr;, and these drugs increase the transactivation of PPAR&ggr; (Endocrinology, 1996, 137, 4189, Cell., 1995, 83, 803, Cell., 1995, 83, 813). Hence, PPAR&ggr;-activator (agonist) that increases the transactivation of PPAR&ggr; is important as antidiabetic drug.
As described, when considering the roles of transcription factor called PPAR on the function on adipocytes and the controlling mechanisms of glucose metabolism and lipid metabolism, if a compound that binds directly to as a ligand of PPAR, in particular, human PPAR and can activate human PPAR could be created, it would be reasonable to expect the medicinal use as a compound that exhibits blood glucose-decreasing action and/or decreasing action of lipids (both of cholesterol and triglyceride) in blood due to very specific mechanism.
For compounds having an affinity to PPAR&agr; as ligands of PPAR&agr;, HEPE (hydroxyeicosapentaenoic acid) produced via oxidation with cytochrome P-450 and eicosanoides in HETE (hydroxyeicosatetraenoic acid) groups, in particular, 8-HETE, 8-HEPE, etc. are reported in addition to LTB
4
, being a metabolite of arachidonic acid (Proc. Natl. Acad. Sci., 1997, 94, 312). However, these endogenous unsaturated fatty acid derivatives are unstable metabolically and chemically and cannot be offered as medicinal drugs.
Moreover, with Troglitazone, the occurrence of serious adverse effect on liver is reported rarely, hence the development of a therapeutic drug for type II diabetes with effectiveness and high safety is being sought.
Now, as compounds with similar structure to the inventive substituted benzylthiazolidine-2,4-dione derivatives, thiazolidine-2,4-dione derivatives in Japanese Unexamined Patent Publication Nos. Sho 55-22636, Sho 60-51189, Sho 61-85372, Sho 61-286376, Hei 1-131169, Hei 2-83384, Hei 5-213913, Hei 8-333355, Hei 9-48771 and Hei 9-169746, European Patent Open No. 0441605, WO-92/07839, etc. are known. However, all of these compounds are thlazolidine-2,4-dione derivatives with different structure from the inventive compounds.
With regard to patents etc. reporting the agonistic effect on PPAR &agr;, WO-97/25042, WO-97/36579, etc. are reported, but all of these have different structure from the inventive compounds and the transactivation function of PPAR&agr; is also never satisfied in strength.
Both the hyperlipidemia and the diabetes are risk factors of arterosclerosis and, from a viewpoint of the prevention of arterosclerosis, in particular, coronary arteroscierosis, the development of a therapeutic drug for metabolic diseases with effectiveness and high safety is desired clinically.
DISCLOSURE OF THE INVENTION
As a result of diligent studies paying an attention to such specific roles on the lipid metabolism of human PPAR, differentiation of adipocytes, etc. aiming at the creation of structurally novel drug with effectiveness and high safety as a therapeutic drug for metabolic diseases, the inventors have found that novel substituted benzylthiazolidine-2,4-dione derivatives represented by the following general formula (1) have excellent transactivation function of human PPAR, and exhibit the blood glucose-decreasing action and the lipid-decreasing action, leading to the completion of the invention.
Namely, the invention relates to substituted benzylthiazolidine-2,4-dione derivatives represented by the general formula (1)
[wherein A denotes a phenyl group which-is unsubstituted or may have substituents, phenoxy group which is unsubstituted or may have substituents or benzyloxy group which is unsubstituted or may have substituents], their medicinally acceptable salts and their hydrates.
The salts of the compounds represented by the general formula (1) in the invention are of common use and metal salts, for example, alkali metal salts (e.g. sodium salt, potassium salt, etc.), alkaline earth metal salts (e.g. calcium salt, magnesium salt, etc.), aluminum salt, and other pharmacologically acceptable salts are mentioned.
Moreover, the compounds represented by the general formula (1) in the invention sometimes include optical isomers based on thiazolidine-2,4-dione ring portion, but all of such isomers and their mixtures are to be included in the scope of the invention.
Furthermore, for the compounds represented by the general formula (1), the existence of various tautomers is considered. These are, for example, as shown in the following formulae.
[wherein A denotes a phenyl group which is unsubstituted or may have substituents, phenoxy group which is unsubstituted or may have substituents or benzyloxy group which is unsubstituted or may have substituents]. In the general formula (1) aforementioned, all of these isomers and their mixtures are to be included in the scope of this invention.
In the general formula (1) of the invention, for the substituents permissible in “phenyl group which is unsubstituted or may have substituents, phenoxy group which is unsubstituted or may have substituents or
Miyachi Hiroyuki
Murakami Koji
Nomura Masahiro
Tanase Takahiro
Tsunoda Masaki
Anderson Rebecca
Kyorin Pharmaceutical Co. Ltd.
McKane Joseph K.
LandOfFree
Substituted benzylthiazolidine-2, 4-dione derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted benzylthiazolidine-2, 4-dione derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted benzylthiazolidine-2, 4-dione derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3256105